Can a new drug combo slow advanced prostate cancer?
NCT ID NCT07730580
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This trial is investigating whether an experimental drug called XNW5004, when combined with standard anti-tumor therapies, can help control advanced prostate cancer. The study involves men with prostate cancer that has spread. Researchers are looking at how safe the combination is and whether it can delay the progression of the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- XNW5004 tablets combined with abiraterone and prednisone or docetaxel and prednisone
- What this could lead to
- If successful, this combination therapy could offer a new treatment option to slow the progression of advanced prostate cancer.
- What could go wrong
- This is an early-phase trial, so the safety and effectiveness of the combination are not yet known. Side effects may occur, and the results may not lead to a standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a new injection tame prostate cancer by cutting testosterone?
- Can a new pill outsmart resistant prostate cancer?
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?
- Can an immune booster make hormone therapy work better against prostate cancer?
- Can a pill outsmart Tumors' defenses?